Search clinical trials for: efgartigimod PH20 SC

Total 565 results

argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Thyroid Eye Disease

United States
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Thyroid Eye Disease

United States
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
argenx

Completed

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Healthy Volunteers

Netherlands
argenx

Completed

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

Generalized Myasthenia Gravis

Spain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
argenx

Active, not recruiting

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

Generalized Myasthenia Gravis

United States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
argenx

Recruiting

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (ADAPT Jr +)

Generalized Myasthenia Gravis

United States, Netherlands, Belgium, Poland, United Kingdom
argenx

Completed

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Bioequivalence

United States
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
argenx

Recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

Korea, Republic of, United States, Bulgaria, Belgium, Denmark, Georgia, Greece, Lithuania, Argentina
argenx

Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

United States, Germany, Spain, Korea, Republic of, Austria, Turkey, Lithuania, Australia, Thailand, Serbia, Poland, Italy, France, Netherlands, Argentina, United Kingdom, Georgia, Belgium, Bulgaria, Canada, Cyprus, Denmark, Greece, Hu... and more
argenx

Completed

SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)

Healthy Volunteers

Netherlands
argenx

Recruiting

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD+)

Bullous Pemphigoid

Netherlands, Spain, Germany, United Kingdom, China, Italy, Hungary, United States, Croatia, Japan, Serbia, Bulgaria, Israel, Australia, Greece, Slovakia
argenx

Active, not recruiting

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)

Bullous Pemphigoid

United States, Australia, Bulgaria, China, Croatia, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS+)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
ViiV Healthcare
GlaxoSmithKline

Not yet recruiting

First Time in Human Study of Long Acting VH4524184 Formulations

HIV Infections

United States
argenx

Not yet recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Myasthenia Gravis
argenx
Iqvia Pty Ltd

Recruiting

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (Rho plus)

Primary Sjögren's Syndrome

Belgium, Hungary, Poland
argenx
Iqvia Pty Ltd

Recruiting

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

United States
argenx

Not yet recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Myasthenia Gravis
argenx

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
argenx
Iqvia Pty Ltd

Active, not recruiting

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Postural Orthostatic Tachycardia Syndrome

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Myasthenia Gravis
argenx

Recruiting

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Renal Impairment

Germany
argenx
Iqvia Pty Ltd

Active, not recruiting

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) (rho)

Primary Sjögren's Syndrome

Belgium, Poland, Hungary, Netherlands
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
argenx

Approved for marketing

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
argenx
Zai Lab Pty. Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (ZL-1103-014)

Membranous Nephropathy

China
argenx
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Lupus Nephritis

China
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
argenx

Withdrawn

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (ADVANCE2)

Primary Immune Thrombocytopenia (ITP)
argenx

Completed

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
argenx

Completed

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Healthy Volunteers

Netherlands
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
University of California, San Diego
University of Oklahoma; University of Southern California; Children's Bureau... and other collaborators

Completed

Evaluating Trauma-Informed, Evidence-Informed Interventions for Latino Families Experiencing Domestic Violence

Interpersonal Relations

United States
StemCells, Inc.

Terminated

Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury

Cervical Spinal Cord Injury | Spine Injury | Cervical Spine Injury

United States, Canada
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Eli Lilly and Company

Completed

A Study of LY3461767 in Healthy Participants

Healthy

United States, Singapore
argenx

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Federal University of Health Science of Porto Alegre
Irmandade Santa Casa de Misericórdia de Porto Alegre

Unknown

Pelvic Physiotherapy in the Prevention of Vaginal Stenosis Secondary to the Radiotherapy (PPPVSSR)

Gynecologic Cancer | Pathological Constriction

Brazil
Eli Lilly and Company

Completed

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3375880 in Healthy Participants

Healthy

United States

Search clinical trials for: efgartigimod PH20 SC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations